Vividion Therapeutics | ApexOnco - Clinical Trials news and analysis

x

“I am very impressed - it has become my go-to platform”

Chief Business Officer

US public biotech company

Click here for more information

Deals

4 April 2025

Bayer still waiting on Vividion

Data insights

18 February 2025

Private US biotechs head for human trials

Halda, Accent and Vividion take more projects into phase 1.

Trial results

1 February 2024

Roche perseveres with FAP

A third discontinuation leaves one anti-FAP project in Roche’s clinical pipeline.

Trial results

18 September 2023

Bayer looks to clinical validation for $1.5bn Vividion deal

Subscribe to Vividion Therapeutics